Natural history of chronic hepatitis B

Clinics in Liver Disease

Volumn 14, Issue 3, 2010, Pages 381-396

  McMahon, Brian J ^a,b  

^a Liver Disease and Hepatitis Program   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

Hepatitis B genotypes; Hepatitis B virus; Hepatocellular carcinoma; Natural history

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

DELTA AGENT HEPATITIS; DISEASE COURSE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MIXED INFECTION; NONHUMAN; PATIENT MONITORING; REVIEW; RISK FACTOR; VACCINATION; VIRUS LOAD; CARCINOMA, HEPATOCELLULAR; COMORBIDITY; COMPLICATION; GENETICS; GEOGRAPHY; HEPATITIS B, CHRONIC; IMMUNOLOGY; LIVER NEOPLASMS; PATHOPHYSIOLOGY; RISK; RNA VIRUS INFECTIONS; VIRUS GENOME;

CARCINOMA, HEPATOCELLULAR; COMORBIDITY; DISEASE PROGRESSION; GENOME, VIRAL; GEOGRAPHY; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; RISK; RISK FACTORS; RNA VIRUS INFECTIONS;

EID: 77954650414     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2010.05.007     Document Type: Review

References (79)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11(2):97-107.
2. McMahon B.J. The natural history of chronic hepatitis B virus infection. Hepatology 2009, 49(5):S45-S55.
3. Beasley R.P., Hwang L.Y., Lee G.C., et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983, 2(8359):1099-1102.
4. Mast E.E., Margolis H.S., Fiore A.E., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005, 54(RR-16):1-31.
5. Coursaget P., Yvonnet B., Chotard J., et al. Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol 1987, 22(1):1-5.
6. Beasley R.P., Hwang L.Y., Lin C.C., et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982, 146(2):198-204.
7. McMahon B.J., Alward W.L., Hall D.B., et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985, 151(4):599-603.
8. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988, 61(10):1942-1956.
9. McMahon B.J., Holck P., Bulkow L., et al. Serologic and clinical outcomes 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001, 135:759-768.
10. Di Marco V., Lo Iacono O., Camma C., et al. The long-term course of chronic hepatitis B. Hepatology 1999, 30(1):257-264.
11. Fattovich G., Brollo L., Giustina G., et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991, 32(3):294-298.
12. Fattovich G., Olivari N., Pasino M., et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008, 57(1):84-90.
13. Yu M.W., Hsu F.C., Sheen I.S., et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997, 145(11):1039-1047.
14. Liaw Y.F., Tai D.I., Chu C.M., et al. The development of cirrhosis in patients with chronic type-B hepatitis-a prospective-study. Hepatology 1988, 8(3):493-496.
15. de Jongh F.E., Janssen H.L., de Man R.A., et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992, 103(5):1630-1635. [see comments].
16. Fattovich G., Giustina G., Schalm S.W., et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995, 21(1):77-82.
17. Realdi G., Fattovich G., Hadziyannis S., et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994, 21(4):656-666.
18. Hoofnagle J.H., Doo E., Liang T.J., et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007, 45(4):1056-1075.
19. Sorrell M.F., Belongia E.A., Costa J., et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 2009, 49(5):S4-S12.
20. Livingston S.E., Simonetti J.P., Bulkow L.R., et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007, 133:1452-1457.
21. Verling J.M. The immunology of hepatitis B. Clin Liver Dis 2007, 11:727-759.
22. Zacharakis G.H., Koskinas J., Kotsiou S., et al. Natural history of chronic HBV infection: a cohort with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-Project). J Med Virol 2005, 77:173-179.
23. de Franchis R., Meucci G., Vecchi M., et al. The natural-history of asymptomatic hepatitis-B surface-antigen carriers. Ann Intern Med 1993, 118(3):191-194.
24. Ahn S.H., Park Y.N., Park J.Y., et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005, 42(2):188-194.
25. Chu C.M., Liaw Y.F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007, 45(5):1187-1192.
26. Simonetti J., Bulkow L., McMahon B.J., et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010, 51:1531-1537.
27. Chen Y.C., Sheen I.S., Chu C.M., et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002, 123(4):1084-1089.
28. Huo T.I., Wu J.C., Lee P.C., et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998, 28(1):231-236. [see comments].
29. Yuen M.F., Wong D.K.H., Fung J., et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008, 135(4):1192-1199.
30. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236.
31. Goldstein S.T., Zhou F.J., Hadler S.C., et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005, 34(6):1329-1339.
32. McMahon B.J., Bulkow L., Harpster A., et al. Screening for hepatocellular carcinoma in Alaska Natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000, 32:842-846.
33. Alberts S.R., Lanier A.P., McMahon B.J., et al. Clustering of hepatocellular-carcinoma in Alaska Native families. Genet Epidemiol 1991, 8(2):127-139.
34. Hainaut P., Boyle P. Curbing the liver cancer epidemic in Africa. Lancet 2008, 371(9610):367-368.
35. Kirk G.D., Bah E., Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis 2006, 27(10):2070-2082.
36. Livingston S.E., Deubner H., McMahon B.J., et al. Steatosis and hepatitis C in an Alaska Native/American Indian population. Int J Circumpolar Health 2006, 65(3):253-260.
37. Wang C.S., Yao W.J., Chang T.T., et al. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev 2009, 18(7):2054-2060.
38. Peng D.D., Han Y., Ding H.G., et al. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J Gastroenterol Hepatol 2008, 23(7):1082-1088.
39. Yun J.W., Cho Y.K., Park J.H., et al. Hepatic steatosis and fibrosis in young men with treatment-naive chronic hepatitis B. Liver Int 2009, 29(6):878-883.
40. Minakari M., Molaei M., Shalmani H.M., et al. Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors. Eur J Gastroenterol Hepatol 2009, 21(5):512-516.
41. Freedman N.D., Everhart J.E., Lindsay K.L., et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009, 50(5):1360-1369.
42. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295(1):65-73.
43. Harris R.A., Chen G., Lin W.Y., et al. Spontaneous clearance of high-titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population. Cancer Causes Control 2003, 14(10):995-1000.
44. Yang H.I., Lu S.N., Liaw Y.F., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002, 347(3):168-174.
45. Yu M.W., Yeh S.H., Chen P.J., et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005, 97(4):265-272.
46. Lok A.S.F., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50(3):661-662.
47. Hui C.K., Leung N., Yuen S.T., et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007, 46(2):395-401.
48. McMahon B.J. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 2009, 3(2):334-342.
49. Chu C.J., Keeffe E.B., Han S.H., et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003, 125(2):444-451.
50. Livingston S.E., Simonetti J.P., McMahon B.J., et al. Hepatitis B virus genotypes in Alaska native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 2007, 195(1):5-11.
51. Kramvis A., Kew M.C., Bukofzer S. Hepatitis B virus precore mutants in serum and liver of Southern African blacks with hepatocellular carcinoma. J Hepatol 1998, 28(1):132-141.
52. Saugauchi F., Orito E., Ichida T., et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003, 124:925-932.
53. Kao J.H. Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 2003, 46(6):400-407.
54. Sakamoto T., Tanaka Y., Simonetti J., et al. Classification of hepatitis B virus genotype B into 2 major types based on characterization of a novel subgenotype in Arctic indigenous populations. J Infect Dis 2007, 196:1487-1492.
55. Hadziyannis S.J., Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001, 34(4):617-624.
56. Yang H.I., Yeh S.H., Chen P.J., et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008, 100(16):1134-1143.
57. Grandjacques C., Pradat P., Stuyver L., et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000, 33(3):430-439.
58. Naoumov N.V., Schneider R., Grotzinger T., et al. Precore mutant hepatitis-B virus infection and liver disease. Gastroenterology 1992, 102(2):538-543.
59. Weinbaum C.M., Mast E.E., Ward J.W. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology 2009, 49(5):S35-S44.
60. Soriano V., Puoti M., Bonacini M., et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005, 19(3):221-240.
61. Hoffmann C.J., Charalambous S., Martin D.J., et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008, 47(11):1479-1485.
62. Thio C.L., Seaberg E.C., Skolasky R., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360(9349):1921-1926.
63. Bendavid E., Bhattacharya J. The president's emergency plan for AIDS relief in Africa: an evaluation of outcomes. Ann Intern Med 2009, 150(10):688-695.
64. Modi A.A., Feld J.J. Viral hepatitis and HIV in Africa. AIDS Rev 2007, 9(1):25-39.
65. Strader D.B. Understudied populations with hepatitis C. Hepatology 2002, 36(5 Suppl 1):S226-S236.
66. Lavanchy D. The global burden of hepatitis C. Liver Int 2009, 29:74-81.
67. Liaw Y.F., Tsai S.L., Chang J.J., et al. Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology 1994, 106(4):1048-1053.
68. Chu C.M., Yeh C.T., Liaw Y.F. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut 1999, 45(4):613-617.
69. Donato F., Boffetta P., Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998, 75(3):347-354.
70. Taylor J.M. Hepatitis delta virus. Virology 2006, 344(1):71-76.
71. Hadziyannis S.J. Hepatitis D. Clin Liver Dis 1999, 3:309-325.
72. Rizzetto M. Hepatitis D: thirty years after. J Hepatol 2009, 50(5):1043-1050.
73. Fattovich G., Giustina G., Christensen E., et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000, 46(3):420-426.
74. Nakano T., Shapiro C.N., Hadler S.C., et al. Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela. J Gen Virol 2001, 82:2183-2189.
75. Hadler S.C., Demonzon M., Ponzetto A., et al. Delta virus-infection and severe hepatitis-an epidemic in the Yucpa Indians of Venezuela. Ann Intern Med 1984, 100(3):339-344.
76. Chang M.H., Chen C.J., Lai M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997, 336(26):1855-1859.
77. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351(15):1521-1531.
78. Beasley RP, Alter HJ, Brandeau ML, et al. Institute of Medicine: Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. In: Colvin HM, Mitchell AE, editors. Washington, DC: National Academies Press; 2010. p. 1-232.
79. Centers for Disease Control and Prevention. Implementation of newborn hepatitis B vaccination-worldwide, 2006. MMWR Morb Mortal Wkly Rep 2008, 57(46):1249-1252.